Overview

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Status:
Suspended

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.

Phase:

Phase 2

Details

Lead Sponsor:

Eben Rosenthal

Collaborator:

National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Dextrans
Diethylenetriamine
Edetic Acid
Panitumumab
Pentetic Acid
Technetium Tc 99m Pentetate